Femasys Inc. (FEMY)
Automate Your Wheel Strategy on FEMY
With Tiblio's Option Bot, you can configure your own wheel strategy including FEMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FEMY
- Rev/Share 0.0676
- Book/Share -0.0573
- PB 11.0839
- Debt/Equity 3.8393
- CurrentRatio 0.0
- ROIC 5.5462
- MktCap 25653232.0
- FreeCF/Share -0.8149
- PFCF -1.2517
- PE -1.0482
- Debt/Assets 0.0
- DivYield 0
- ROE -3.9243
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed ® , and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on expanding the U.S. infertility …
Read More
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.19 per share a year ago.
Read More
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Company expands commercial product offering with FemBloc ® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update.
Read More
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Femasys continues to expand access and market share for its first-line infertility treatment option Femasys continues to expand access and market share for its first-line infertility treatment option
Read More
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
Published: March 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces the Company has secured strategic distribution partnerships for FemBloc® in Spain. Comercial Medico Quirurigca, SA (CMQ) will expand its commercial portfolio to include FemBloc, alongside other Femasys products in northern Spain, while Durgalab will handle distribution in the southern region.
Read More
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Medicines & Healthcare products Regulatory Agency (MHRA) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection. “This is another key milestone as we expand our reach to the UK following successful approval across Europe for our innovative infertility and cancer detection products.
Read More
About Femasys Inc. (FEMY)
- IPO Date 2021-06-18
- Website https://www.femasys.com
- Industry Medical - Instruments & Supplies
- CEO Ms. Kathy Lee-Sepsick M.B.A.
- Employees 69